Tags: healthcare technology

A Harvard-led trial comparing OpenAI's o1 reasoning model with human physicians in a Boston emergency department showed the AI correctly identified the exact or near‑exact diagnosis in 67% of cases, outpacing doctors who scored between 50% and 55%. When provided with more detailed patient information, the model's accuracy rose to 82% versus 70%‑79% for clinicians. Researchers caution the findings are not statistically significant and note the AI cannot assess visual cues or patient demeanor, but suggest the technology could serve as a rapid second opinion in emergency care. Read more

Corti, the Copenhagen‑based health AI company, introduced Symphony for Medical Coding, an agentic system that treats coding as a reasoning task rather than simple labeling. Built on a peer‑reviewed framework and a study of 1.8 million patient encounters, Symphony claims up to 25% higher clinical accuracy than models from OpenAI, Anthropic, Amazon, Oracle and Microsoft. The system uses four sequential agents to extract evidence, navigate the ICD index, validate candidates and reconcile final codes, delivering auditable outputs linked to supporting clinical evidence. Available through an API and integrated with the Corti Console, Symphony operates across U.S. and European coding environments and aims to reduce errors that affect billing, reporting and public health data. Read more

Parallel, a Paris‑based startup founded in 2024, announced a $20 million Series A round led by Index Ventures. The funding will accelerate the rollout of its AI agents that automate hospital administrative workflows such as medical coding, billing, and admissions. By operating on top of existing hospital software rather than requiring deep integration, Parallel claims hospitals can deploy the solution within a week. The company already has agents in use at several dozen public and private hospitals in France and plans to expand across the Netherlands, Belgium, and other European markets. Read more

Biotech firms are turning to artificial intelligence to boost productivity and address talent shortages. Insilico Medicine is building a multi‑task AI platform that can generate disease hypotheses, design candidate molecules and even repurpose existing drugs, aiming to speed drug discovery and cut costs. GenEditBio is using AI to design engineered protein delivery vehicles that target specific tissues for in‑vivo CRISPR therapy, recently receiving FDA clearance for a corneal‑dystrophy trial. Both companies stress the need for richer, more diverse data to improve model accuracy and envision future tools such as digital twins for virtual clinical testing. Read more

Counterforce Health, founded by Neal Shah, offers a free AI‑driven platform that creates customized insurance appeal letters in minutes. As insurers increasingly rely on AI to reject claims—sometimes denying thousands of requests in weeks—patients face a daunting and time‑consuming appeals process. Counterforce’s system analyzes denial letters, policy language, medical literature, and successful past appeals to produce evidence‑based drafts that users can edit and submit. Backed by grants and venture funding, the tool aims to level the playing field for individuals who cannot afford professional advocates, making the appeals process faster, cheaper, and more accessible. Read more

Inflo Health, co-founded by nurse Angela Adams and CTO Nate Sutton, uses artificial intelligence to scan radiology reports, flag incidental findings and automate patient follow‑up notifications. The platform addresses a documented 50% non‑adherence rate for radiology follow‑up recommendations, reducing manual tracking and escalating urgent cases to care coordinators. With AI handling 60%‑70% of straightforward follow‑ups, hospitals such as East Alabama Medical Center have seen a 74% increase in completed follow‑ups, and the company reports that 125,000 lives have been impacted to date. Read more

Counterforce Health, founded by Neal Shah, offers a free AI‑driven service that creates customized appeal letters for denied health‑insurance claims. The platform analyzes denial letters, insurance policies and medical literature to produce evidence‑based drafts that patients can edit and submit. It aims to level the playing field as insurers increasingly rely on AI to reject claims quickly. By providing a cost‑free tool, Counterforce seeks to empower individuals who might otherwise lack the resources to fight complex denials, addressing a growing frustration in the U.S. healthcare system. Read more

AI psychosis refers to delusional or obsessive behavior linked to extensive use of chatbot systems. Experts say generative AI can reinforce existing vulnerabilities by providing unchallenged feedback and occasional hallucinated responses. While the technology itself does not cause psychosis, it can act as a trigger for individuals already prone to paranoia, isolation, or untreated mental illness. Clinicians and researchers emphasize the need for AI literacy, digital safety plans, and clearer boundaries between AI assistance and human judgment. Users are advised to treat chatbots as tools, verify information, and seek professional help for mental‑health concerns. Read more